Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Adult Annular Pancreas Presenting With Gastric Outlet Obstruction Following Semaglutide Initiation: A Case Report
Cureus, 2026;18(6):e111636
From dual to quintuple agonism for next-generation pharmacology to treat obesity and type 2 diabetes: synergistic incretin and nuclear receptor signaling
Cardiovascular diabetology. Endocrinology reports, 2026;12(1)
GLP-1 Receptor Agonists in Obstructive Sleep Apnea: A Propensity Score-Matched Real-World Analysis
Respiratory medicine, 2026;:109001
From evidence to practice: Identifying candidates for semaglutide in chronic atherosclerotic disease
International journal of cardiology, 2026;:134646
High-yield recombinant production of the semaglutide main chain P29 intermediate using SNAC-tagged enterokinase-cleavable fusion peptides
PloS one, 2026;21(6):e0348509
Copper peptide activated cascade catalysis for glucose regulation and hypoxia reversing in infected diabetic wound healing
Materials today. Bio, 2026;39:103396
GLP-1 Receptor Agonists or Dual GLP-1/GIP Receptor Agonists vs. SGLT2 Inhibitors in Patients with Atrial Fibrillation and HFpEF: A Propensity-Matched Real-World Analysis
Journal of clinical medicine, 2026;15(13)
Surgery on Patients Taking Glucagon-Like Peptide-1 Receptor Agonists
Advances in surgery, 2026;60(1):285-298
Repurposed Drugs and Cardiovascular Morbidity: A Cost-Effectiveness Analysis
American journal of therapeutics, 2026
Cost-Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction-Associated Steatohepatitis With Significant Fibrosis in the United States
Diabetes, obesity & metabolism, 2026
Real-World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery
Obesity (Silver Spring, Md.), 2026
Papillary thyroid carcinoma discovered in a patient on semaglutide therapy for metabolic syndrome: a case presentation and review of current evidence
Hormones (Athens, Greece), 2026
Hydrophobic ion pairing formed semaglutide designed for oral self-microemulsifying delivery in diabetes treatment
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2026;:115167
The risk of retinal vascular events in patients using semaglutide: a scoping review
Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 2026;:1-41
Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 Trials
Diabetes, obesity & metabolism, 2026
Access Barriers and Variable Response to Semaglutide in Severe Adolescent Obesity: A Case Series
Case reports in pediatrics, 2026;2026:5562574
Do Fasting GLP-1 and GIP Levels Predict the Initial Pharmacological Response to Semaglutide and Tirzepatide?
Diagnostics (Basel, Switzerland), 2026;16(13)
Possible Attenuation of Early Weight Loss During Tirzepatide Therapy in a Patient Treated With Levosulpiride: A Case Report and Mechanistic Hypothesis
Cureus, 2026;18(6):e111508
Peptide Hormones in Appetite Regulation: A Complex Network
Pharmaceuticals (Basel, Switzerland), 2026;19(7)
Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis
La Clinica terapeutica;177(4):877-886